Misplaced Pages

Avatrombopag

Clinical data
Pronunciation	a" va trom' boe pag
Trade names	Doptelet
AHFS/Drugs.com	Monograph
MedlinePlus	a618032
License data	US DailyMed: Avatrombopag
Pregnancy category	AU: B3
Routes of administration	By mouth
ATC code	B02BX08 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Identifiers
IUPAC name 1-carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
CAS Number	570406-98-3
PubChem CID	9852519
DrugBank	DB11995
ChemSpider	8028230
UNII	3H8GSZ4SQL
KEGG	D10306 as salt: D10307
ChEMBL	ChEMBL2103883
CompTox Dashboard (EPA)	DTXSID30205667
Chemical and physical data
Formula	C29H34Cl2N6O3S2
Molar mass	649.65 g·mol
3D model (JSmol)	Interactive image
SMILES C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
InChI InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) Key:OFZJKCQENFPZBH-UHFFFAOYSA-N
(what is this?)

Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.

It acts as a thrombopoietin receptor agonist.

References

1. ^ "Doptelet". Therapeutic Goods Administration (TGA). 30 January 2023. Archived from the original on 5 February 2023. Retrieved 8 April 2023.
2. "Doptelet (Swedish Orphan Biovitrum Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 8 April 2023.
3. "AusPAR: Doptelet". Therapeutic Goods Administration (TGA). 8 February 2024. Retrieved 31 March 2024.
4. "Details for: Doptelet". Health Canada. 22 January 2024. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
5. "Summary Basis of Decision for Doptelet". Health Canada. 17 May 2024. Retrieved 8 June 2024.
6. "Doptelet- avatrombopag maleate tablet, film coated". DailyMed. 1 July 2021. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
7. ^ "Doptelet EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 22 May 2020. Retrieved 2 May 2020.
8. Abdela J (2019). "Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag". Clinical Medicine Insights. Blood Disorders. 12: 1179545X19875105. doi:10.1177/1179545X19875105. PMC 6804364. PMID 31673229.
9. Markham A (November 2021). "Avatrombopag: A Review in Thrombocytopenia". Drugs. 81 (16): 1905–1913. doi:10.1007/s40265-021-01613-y. PMC 8610948. PMID 34709601.
10. "FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2018. Archived from the original on 11 December 2019. Retrieved 2 May 2020.
11. "Drug Approval Package: Doptelet (avatrombopag)". U.S. Food and Drug Administration (FDA). 28 June 2018. Archived from the original on 7 April 2021. Retrieved 2 May 2020.
12. Kuter DJ (November 2021). "The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag". Blood Reviews. 53: 100909. doi:10.1016/j.blre.2021.100909. PMID 34815110. S2CID 244285488.

• Medicine

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs acting on the blood and blood forming organs
• Orphan drugs
• Thrombopoietin receptor agonists
• Thiophenes
• Chloropyridines
• Thiazoles
• Piperazines
• Cyclohexyl compounds
• Blood and blood forming organ drug stubs